Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

280.32USD
23 Jun 2017
Change (% chg)

$-0.25 (-0.09%)
Prev Close
$280.57
Open
$282.33
Day's High
$284.46
Day's Low
$277.58
Volume
2,439,595
Avg. Vol
1,641,961
52-wk High
$333.65
52-wk Low
$223.02

BIIB.O

Chart for BIIB.O

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $59,513.16
Shares Outstanding(Mil.): 212.12
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 17.59 14.08 19.12
EPS (TTM): 15.95 -- --
ROI: 19.24 -6.75 -5.05
ROE: 31.91 -6.20 -4.29

BRIEF-Biogen’s Imraldi granted positive opinion by committee for medicinal products for human use

* Biogen’s Imraldi, an adalimumab biosimilar candidate referencing Humira, granted positive opinion by committee for medicinal products for human use

Jun 23 2017

BRIEF-Biogen appoints Ginger Gregory as chief human resources officer

* Biogen appoints Ginger Gregory executive vice president, chief human resources officer

Jun 20 2017

US STOCKS-Wall St at record highs on technology, health stocks strength

* Fed's Dudley says tight labor market should push inflation up

Jun 19 2017

Alexion taps Biogen veteran Paul Clancy as CFO

Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.

Jun 13 2017

UPDATE 1-Alexion taps Biogen veteran Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.

Jun 13 2017

REFILE-Alexion names Biogen's Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31.

Jun 13 2017

BRIEF-Alexion Pharmaceuticals names Paul Clancy as CFO

* Alexion Pharmaceuticals Inc - Clancy will succeed Dave Anderson, who will continue to serve as CFO until july 31, 2017

Jun 13 2017

EU approves Biogen's Spinraza for lead genetic cause of infant death

Biogen Inc on Thursday said its drug, Spinraza, had secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.

Jun 01 2017

EU approves Biogen's Spinraza for lead genetic cause of infant death

Biogen Inc on Thursday said its drug, Spinraza, had secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.

Jun 01 2017

EU approves Biogen's Spinraza for lead genetic cause of infant death

June 1 Biogen Inc on Thursday said its drug, Spinraza, had secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.

Jun 01 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $136.43 +0.38
Pfizer Inc. (PFE.N) $34.17 +0.11
Novartis AG (NOVN.S) CHF83.70 -0.10
Merck & Co., Inc. (MRK.N) $66.16 +0.14
Roche Holding Ltd. (ROG.S) CHF252.80 0.00
Roche Holding Ltd. (RO.S) CHF254.25 -1.75
Bayer AG (BAYGn.DE) €121.90 -0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.87 -0.78
GlaxoSmithKline plc (GSK.L) 1,708.50 -13.50

Earnings vs. Estimates